Medical Advances Account For Half Of CDER 2013 NMEs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fourteen first-in-class and advance-in-class NMEs were approved by CDER in 2013, accounting for 52% of new drug approvals. The most innovative drugs represent a lower share of approvals in 2013 compared with recent years, but the total of nine first-in-class NMEs is in line with the 25-year average.